GlassScriptPhysician profile
Chetan Bhardwaj
NPI 1891950713
$4,935.15
in general payments reported to CMS, 2019-2025
21 companies · $127 in 2025
The $127 reported for 2025 was less than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $861 · 2020: $45.13 · 2021: $122 · 2022: $1,493 · 2023: $2,001 · 2024: $285 · 2025: $127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,191 · Travel and Lodging: $1,127 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,190.57 |
| Travel and Lodging | $1,127.25 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,324.84 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Mitraclip, Cardiomems |
| Janssen Pharmaceuticals, INC | $275.89 | 2019-2023 | Xarelto |
| Abiomed | $248.84 | 2019-2024 | Impella |
| Livanova USA, INC. | $178.23 | 2020-2023 | Lifesparc |
| United Therapeutics Corporation | $144.52 | 2019-2025 | Tyvaso, Orenitram, Remodulin |
| Pfizer INC. | $142.09 | 2019-2022 | |
| Impulse Dynamics (USA) INC. | $125.54 | 2023 | Optimizer |
| Actelion Pharmaceuticals US, INC. | $94.99 | 2023 | Opsumit, Uptravi |
| Cvrx, INC. | $79.61 | 2024 | Barostim Neo System |
| Medtronic Vascular, INC. | $64.26 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $62.54 | 2019 | |
| Merck Sharp & Dohme LLC | $48.36 | 2022 | |
| Endotronix, INC. | $32.25 | 2025 | Cordella Pulomonary Artery Pressure Sensor |
| Amgen INC. | $27.00 | 2019 | |
| Eurofins Viracor, LLC | $26.64 | 2023 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $22.48 | 2023 | Swan-Ganz |
| Astrazeneca Pharmaceuticals LP | $18.65 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $18.42 | 2024-2025 | Lifevest |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chetan Bhardwaj listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.